ProfileGDS5678 / 1430240_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 61% 61% 60% 64% 63% 61% 60% 61% 61% 60% 65% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7931463
GSM967853U87-EV human glioblastoma xenograft - Control 23.6452361
GSM967854U87-EV human glioblastoma xenograft - Control 33.6526461
GSM967855U87-EV human glioblastoma xenograft - Control 43.580661
GSM967856U87-EV human glioblastoma xenograft - Control 53.5615260
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8817664
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8215263
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6234761
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5873660
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6258561
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6714261
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5769260
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8928765
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6434361